5:00 PM ET
8-K
Executive Compensation
TScan Therapeutics Executive Compensation
TScan Therapeutics entered into separation agreements with its outgoing CFO, Jason A. Amello, and CMO, Dr. Chrystal Louis, following a strategic reorganization. The agreements provide for continued salary and benefits through November 1, 2026, and include potential milestone-based cash awards of $85,000 and $125,000, respectively, under a 2025 retention program.
- Counterparty
- Jason A. Amello and Chrystal Louis, M.D., MPH
- Term
- through Nov 1, 2026